| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis |
The following tables set forth the fair value of financial instruments that were measured at fair value on a recurring basis (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | As of June 30, 2026 | | Level 1 | | Level 2 | | Level 3 | | Total | | Financial Assets: | | | | | | | | | Cash equivalents | | | | | | | | | | | | | | | | | Money market funds | $ | 18,775 | | | $ | — | | | $ | — | | | $ | 18,775 | | | Available-for-sale securities | | | | | | | | | U.S. Treasury securities | $ | 132,821 | | | $ | — | | | $ | — | | | $ | 132,821 | | | Corporate debt securities | $ | — | | | $ | 389,632 | | | $ | — | | | $ | 389,632 | | | Total financial assets | $ | 151,596 | | | $ | 389,632 | | | $ | — | | | $ | 541,228 | | | Financial Liabilities: | | | | | | | | | Contingent obligation | $ | 3,288 | | | $ | — | | | $ | — | | | $ | 3,288 | | | Total financial liabilities | $ | 3,288 | | | $ | — | | | $ | — | | | $ | 3,288 | |
| | | | | | | | | | | | | | | | | | | | | | | | | As of December 31, 2025 | | Level 1 | | Level 2 | | Level 3 | | Total | | Financial Assets: | | | | | | | | | Cash equivalents | | | | | | | | | Money market funds | $ | 6,157 | | | $ | — | | | $ | — | | | $ | 6,157 | | | Available-for-sale securities | | | | | | | | | U.S. Treasury securities | $ | 12,076 | | | $ | — | | | $ | — | | | $ | 12,076 | | | Corporate debt securities | $ | 39,399 | | | $ | — | | | $ | — | | | $ | 39,399 | | | Total financial assets | $ | 57,632 | | | $ | — | | | $ | — | | | $ | 57,632 | | | Financial Liabilities: | | | | | | | | | Contingent obligation | $ | — | | | $ | — | | | $ | 1,828 | | | $ | 1,828 | | | Total financial liabilities | $ | — | | | $ | — | | | $ | 1,828 | | | $ | 1,828 | |
|
| Schedule of Error Corrections and Prior Period Adjustments |
Included below is a summary of the previously reported amounts, the impact of these adjustments and the as-adjusted amounts for each of the impacted periods. | | | | | | | | | | | | | | | | | | | Condensed Consolidated Statements of Operations and Comprehensive Loss | | | | | | | | Three Months Ended March 31, 2026 | | As Reported | | Adjustments | | As Adjusted | | Revenue | | | | | | | Product revenue | $ | 3,150 | | | $ | 446 | | | $ | 3,596 | | | Total revenue | $ | 9,461 | | | $ | 446 | | | $ | 9,907 | | | Cost of revenue: | | | | | | | Cost of products | $ | 2,830 | | | $ | (98) | | | $ | 2,732 | | | Total cost of revenue | $ | 7,470 | | | $ | (98) | | | $ | 7,372 | | | Gross profit | $ | 1,991 | | | $ | 544 | | | $ | 2,535 | | | Loss from operations | $ | (33,575) | | | $ | 544 | | | $ | (33,031) | | | Loss before income taxes | $ | (30,263) | | | $ | 544 | | | $ | (29,719) | | | Net loss | $ | (30,263) | | | $ | 544 | | | $ | (29,719) | | | Comprehensive loss | $ | (31,244) | | | $ | 544 | | | $ | (30,700) | | | Net loss per share attributable to common stockholders - basic and diluted | $ | (0.26) | | | $ | 0.01 | | | $ | (0.25) | | | Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted | $ | 118,162,332 | | | $ | 118,162,332 | | | $ | 118,162,332 | |
| | | | | | | | | | | | | | | | | | | Condensed Consolidated Statements of Cash Flows | | | | | | | | Three Months Ended March 31, 2026 | | As Reported | | Adjustments | | As Adjusted | | Cash flows from operating activities | | | | | | | Net loss | $ | (30,263) | | | $ | 544 | | | $ | (29,719) | | | Changes in operating assets and liabilities: | | | | | | | Unbilled receivables | $ | (255) | | | $ | (446) | | | $ | (701) | | | Accrued liabilities | $ | (216) | | | $ | (98) | | | $ | (314) | | | Net cash used in operating activities | $ | (19,159) | | | $ | — | | | $ | (19,159) | |
| | | | | | | | | | | | | | | | | | | Condensed Consolidated Statements of Operations and Comprehensive Loss | | | | | | | | Nine Months Ended September 30, 2025 | | As Reported | | Adjustments | | As Adjusted | | Revenue | | | | | | | Product revenue | $ | 15,987 | | | $ | (891) | | | $ | 15,096 | | | Total revenue | $ | 21,674 | | | $ | (891) | | | $ | 20,783 | | | Cost of revenue: | | | | | | | Cost of products | $ | 10,651 | | | $ | (728) | | | $ | 9,923 | | | Total cost of revenue | $ | 13,590 | | | $ | (728) | | | $ | 12,862 | | | Gross profit | $ | 8,084 | | | $ | (163) | | | $ | 7,921 | | | Loss from operations | $ | (23,732) | | | $ | (163) | | | $ | (23,895) | | | Loss before income taxes | $ | (21,035) | | | $ | (163) | | | $ | (21,198) | | | Net loss | $ | (21,035) | | | $ | (163) | | | $ | (21,198) | | | Comprehensive loss | $ | (20,740) | | | $ | (163) | | | $ | (20,903) | | | Net loss per share attributable to common stockholders - basic and diluted | $ | (0.46) | | | $ | (0.01) | | | $ | (0.47) | | | Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted | 45,456,929 | | 45,456,929 | | 45,456,929 |
| | | | | | | | | | | | | | | | | | | Condensed Consolidated Statements of Cash Flows | | | | | | | | Nine Months Ended September 30, 2025 | | As Reported | | Adjustments | | As Adjusted | | Cash flows from operating activities | | | | | | | Net loss | $ | (21,035) | | | $ | (163) | | | $ | (21,198) | | | Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | Unbilled receivables | $ | (231) | | | $ | 891 | | | $ | 660 | | | Accrued liabilities | $ | 324 | | | $ | (728) | | | $ | (404) | | | Net cash used in operating activities | $ | (15,945) | | | $ | — | | | $ | (15,945) | |
| | | | | | | | | | | | | | | | | | | Consolidated Balance Sheets | | | | | | | | As of December 31, 2025 | | As Reported | | Adjustments | | As Adjusted | | ASSETS | | | | | | | CURRENT ASSETS: | | | | | | | Unbilled receivables | $ | 4,734 | | | $ | (2,097) | | | $ | 2,637 | | | Total current assets | $ | 74,624 | | | $ | (2,097) | | | $ | 72,527 | | | TOTAL ASSETS | $ | 115,313 | | | $ | (2,097) | | | $ | 113,216 | | | LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) | | | | | | | CURRENT LIABILITIES: | | | | | | | Accrued liabilities | $ | 8,610 | | | $ | 313 | | | $ | 8,923 | | | Total current liabilities | $ | 22,672 | | | $ | 313 | | | $ | 22,985 | | | TOTAL LIABILITIES | $ | 26,746 | | | $ | 313 | | | $ | 27,059 | | | Stockholders’ Equity (Deficit): | | | | | | | Accumulated deficit | $ | (231,086) | | | $ | (2,410) | | | $ | (233,496) | | | Total Stockholders' Equity (Deficit) | $ | (208,247) | | | $ | (2,410) | | | $ | (210,657) | | | Total Liabilities, Convertible Redeemable Preferred Stock and Stockholders’ Equity (Deficit) | $ | 115,313 | | | $ | (2,097) | | | $ | 113,216 | |
| | | | | | | | | | | | | | | | | | | Consolidated Statements of Operations and Comprehensive Loss | | | | | | | | For the period ended December 31, 2025 | | As Reported | | Adjustments | | As Adjusted | | Revenue | | | | | | | Product revenue | $ | 19,614 | | | $ | (1,356) | | | $ | 18,258 | | | Total revenue | $ | 32,464 | | | $ | (1,356) | | | $ | 31,108 | | | Cost of revenue: | | | | | | | Cost of products | $ | 13,558 | | | $ | (923) | | | $ | 12,635 | | | Total cost of revenue | $ | 20,651 | | | $ | (923) | | | $ | 19,728 | | | Gross profit | $ | 11,813 | | | $ | (433) | | | $ | 11,380 | | | Loss from operations | $ | (35,286) | | | $ | (433) | | | $ | (35,719) | | | Loss before income taxes | $ | (31,795) | | | $ | (433) | | | $ | (32,228) | | | Net loss | $ | (31,795) | | | $ | (433) | | | $ | (32,228) | | | Comprehensive loss | $ | (31,249) | | | $ | (433) | | | $ | (31,682) | | | Net loss per share attributable to common stockholders - basic and diluted | $ | — | | | $ | — | | | $ | — | | | Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted | $ | 46,186 | | | $ | 46,186 | | | $ | 46,186 | |
| | | | | | | | | | | | | | | | | | | Consolidated Statements of Cash Flows | | | | | | | | Year Ended December 31, 2025 | | As Reported | | Adjustments | | As Adjusted | | Cash flows from operating activities | | | | | | | Net loss | $ | (31,795) | | | $ | (433) | | | $ | (32,228) | | | Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | Unbilled receivables | $ | (1,176) | | | $ | 1,356 | | | $ | 180 | | | Accrued liabilities | $ | (493) | | | $ | (923) | | | $ | (1,416) | | | Net cash used in operating activities | $ | (24,145) | | | $ | — | | | $ | (24,145) | |
| | | | | | | | | | | | | | | | | | | Consolidated Statements of Operations and Comprehensive Loss | | | | | | | | For the period ended December 31, 2024 | | As Reported | | Adjustments | | As Adjusted | | Revenue | | | | | | | Product revenue | $ | 22,325 | | | $ | (742) | | | $ | 21,583 | | | Total revenue | $ | 28,836 | | | $ | (742) | | | $ | 28,094 | | | Cost of revenue: | | | | | | | Cost of products | $ | 17,571 | | | $ | 1,236 | | | $ | 18,807 | | | Total cost of revenue | $ | 19,772 | | | $ | 1,236 | | | $ | 21,008 | | | Gross profit | $ | 9,064 | | | $ | (1,978) | | | $ | 7,086 | | | Loss from operations | $ | (53,008) | | | $ | (1,978) | | | $ | (54,986) | | | Loss before income taxes | $ | (53,766) | | | $ | (1,978) | | | $ | (55,744) | | | Net loss | $ | (53,764) | | | $ | (1,978) | | | $ | (55,742) | | | Comprehensive loss | $ | (53,290) | | | $ | (1,978) | | | $ | (55,268) | | | Net loss per share attributable to common stockholders - basic and diluted | $ | (1.35) | | | $ | (0.05) | | | $ | (1.40) | | | Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted | $ | 39,808,027 | | | $ | 39,808,027 | | | $ | 39,808,027 | |
| | | | | | | | | | | | | | | | | | | Consolidated Statements of Cash Flows | | | | | | | | Year Ended December 31, 2024 | | As Reported | | Adjustments | | As Adjusted | | Cash flows from operating activities | | | | | | | Net loss | $ | (53,764) | | | $ | (1,978) | | | $ | (55,742) | | | Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | Unbilled receivables | $ | (2,254) | | | $ | 742 | | | $ | (1,512) | | | Accrued liabilities | $ | 3,563 | | | $ | 1,236 | | | $ | 4,799 | | | Net cash used in operating activities | $ | (32) | | | $ | — | | | $ | (32) | |
|